

June 2, 2017

Pharmacy Announcement

Preferred Drug List (PDL) Changes Effective June 1, 2017

On March 23, 2017, the Pharmacy and Therapeutics (P&T) Committee of the Nevada Department of Health and Human Services' Division of Health Care Financing and Policy met to review new and existing therapeutic drug classes on the Nevada Medicaid Preferred Drug List (PDL).

The actions taken by the committee are indicated below. All changes are effective June 1, 2017. The complete PDL is posted on the "[Preferred Drug List](#)" webpage.

Drug Class	Drugs Added as Preferred	Drugs Added as Non-Preferred
Cardiovascular Agents: Antihypertensive Agents: Vasodilators - Oral		Upravi®
Hormones and Hormone Modifiers: Antidiabetic Agents – Insulins (Vials, Pens and Inhaled)		Basaglar®
Ophthalmic Agents: Ophthalmics for Dry Eye Disease	Restasis®	Xiidra®
Psychotropic Agents: Antipsychotics: Atypical Antipsychotics - Oral		Quetiapine XR
Respiratory Agents: Respiratory Beta-Agonists: Short-Acting Respiratory Beta-Agonists		Levalbuterol HFA

In addition, Evzio® has been removed from the Toxicology Agents: Antidotes: Opiate Antagonists drug class of the Nevada Medicaid Preferred Drug List. The manufacturer no longer participates in the Federal Drug Rebate Program.